Equities Analysts Issue Forecasts for ARWR FY2031 Earnings

Key Points

• HC Wainwright forecasts Arrowhead Pharmaceuticals will earn $9.61 per share in FY2031 and maintains a Buy rating with a $120 price target, compared with a current full-year consensus estimate of a $3.62 per-share loss.
• Arrowhead’s latest quarter missed EPS expectations, reporting a $1.36 loss per share versus the $1.23 expected, although revenue of $75.25 million rose 171% year over year and exceeded estimates.
• Analyst sentiment remains bullish, with 11 Buy ratings and a consensus price target of $99.07; recent ARO-MAPT data also showed tau reductions of up to 73%, supporting the potential of Arrowhead’s TRiM platform for neurological diseases.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Research analysts at HC Wainwright issued their FY2031 EPS estimates for shares of Arrowhead Pharmaceuticals in a report released on Thursday, October 15th. HC Wainwright analyst P. Trucchio anticipates that the biotechnology company will post earnings of $9.61 per share for the year. HC Wainwright currently has a "Buy" rating and a $120.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($3.62) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The business had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm's revenue for the quarter was up 171.0% on a year-over-year basis. During the same period in the prior year, the company earned ($1.26) earnings per share.

A number of other equities research analysts also recently commented on ARWR. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a "buy" rating and a $98.00 price objective for the company. B. Riley Financial lifted their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a report on Thursday, September 24th. They issued a "neutral" rating and a $74.00 target price on the stock. Piper Sandler reiterated an "overweight" rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Finally, UBS Group assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Thursday. They issued a "buy" rating and a $109.00 price target for the company. Eleven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Trading Up 0.2%

Arrowhead Pharmaceuticals stock opened at $58.50 on Friday. The firm has a market cap of $8.24 billion, a price-to-earnings ratio of -26.00 and a beta of 1.29. Arrowhead Pharmaceuticals has a 1 year low of $36.57 and a 1 year high of $95.49. The firm's 50 day moving average price is $76.16 and its two-hundred day moving average price is $76.00. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Michael S. Perry sold 11,600 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the sale, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director directly owned 31,600 shares of the company's stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth about $1,208,838,000. Jupiter Topco LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at approximately $99,623,000. Renaissance Technologies LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 1st quarter valued at approximately $64,988,000. Bank of New York Mellon Corp bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at approximately $70,061,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Arrowhead Pharmaceuticals in the second quarter worth approximately $50,990,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Interim Phase 1/2a data showed ARO-MAPT crossed the blood-brain barrier and produced deep, durable tau reductions of up to 73% in healthy volunteers. Arrowhead said the results represent initial clinical validation of its TRiM™ CNS delivery platform, potentially expanding its ability to develop RNAi medicines for neurological diseases. Arrowhead ARO-MAPT interim clinical data
• Positive Sentiment: Coverage of the Alzheimer’s results emphasized the potential breakthrough of delivering gene-silencing medicine into the brain, while follow-up commentary described the findings as unlocking a broader platform for central nervous system diseases. ARWR interim ARO-MAPT data
• Positive Sentiment: Analyst sentiment remains strongly bullish: UBS initiated coverage with a Buy rating and a $109 price target, while Chardan Capital and HC Wainwright reaffirmed Buy ratings with targets of $115 and $120, respectively. These targets imply substantial potential upside if ARO-MAPT and the TRiM platform continue to progress. Arrowhead analyst ratings

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.